Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | KDR | P35968 | 7/20 | 0.46 |
| ▸ | PDGFRB | P09619 | 4/20 | 0.46 |
| ▸ | AURKA | O14965 | 1/20 | 0.44 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.44 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.44 |
| ▸ | FLT3 | P36888 | 2/20 | 0.43 |
| ▸ | LCK | P06239 | 1/20 | 0.43 |
| ▸ | CSF1R | P07333 | 1/20 | 0.43 |
| ▸ | KIT | P10721 | 1/20 | 0.43 |
| ▸ | FLT1 | P17948 | 1/20 | 0.43 |
| ▸ | FLT4 | P35916 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4255792 | 0.86 | POLB (0.54) | CA12CA1CA2CA9KDR | |
| SCHEMBL4257241 | 0.86 | RIPK2 (0.55) | KMT2ACA12CA1CA2CA9 | |
| SCHEMBL6613867 | 0.85 | KDR (0.62) | KMT2AKDRPDGFRBAURKAIKBKE | |
| SCHEMBL4260093 | 0.83 | AURKB (0.63) | KDRPDGFRBAURKAIKBKEAURKB | |
| SCHEMBL4258772 | 0.83 | KDR (0.56) | KDRPDGFRBAURKAAURKBFLT3 | |
| SCHEMBL4254915 | 0.83 | KDR (0.56) | KMT2ACA12CA1CA2CA9 | |
| SCHEMBL4257173 | 0.82 | KDR (0.58) | KMT2AKDRPDGFRBAURKAAURKB | |
| SCHEMBL4262218 | 0.81 | SRC (0.54) | KMT2ACA12CA1CA2CA9 | |
| SCHEMBL4254757 | 0.81 | KDR (0.49) | KMT2AKDRPDGFRBAURKAIKBKE | |
| SCHEMBL4263118 | 0.81 | BTK (0.55) | CA12CA1CA2CA9POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7307097-B2 | Chemical compounds | SMITHKLINE BEECHMAN CORPORATION (US) | 2007-12-11 | — | — | US | claimed |
| EP-1436265-A4 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2004-12-15 | — | — | EP | claimed |
| EP-1436265-A2 | CHEMICAL COMPOUNDS | SmithKline Beecham Corporation (US) | 2004-07-14 | — | — | EP | claimed |
| WO-2003072541-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-09-04 | — | — | WO | claimed |
| US-20090012309-A1 | CHEMICAL COMPOUNDS | ADAMS JERRY LEROY | 2009-01-08 | — | — | US | disclosed |
| US-7307097-B2 | Chemical compounds | SMITHKLINE BEECHMAN CORPORATION (US) | 2007-12-11 | — | — | US | disclosed |
| EP-1436265-A4 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2004-12-15 | — | — | EP | disclosed |
| US-20040198986-A1 | 5-amino-1,3-substituted pyrazole-4-carboxylic acid amides of given formula, such as 5-Amino-1-tert-butyl-3-{4-[3-(2-fluoro-5-trifluoromethyl-phenyl)-ureido]-phenyl}-1H-pyrazole-4-carboxylic acid amide; treating cancer; receptor tyrosine kinase inhibitors | SMITHKLINE BEECHAM CORPORATION | 2004-10-07 | — | — | US | disclosed |
| EP-1436265-A2 | CHEMICAL COMPOUNDS | SmithKline Beecham Corporation (US) | 2004-07-14 | — | — | EP | disclosed |
| WO-2003072541-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012309-A1 | CHEMICAL COMPOUNDS | CYP11B2, CYP3A43, CYP3A5 | KMT2A 2911/4885CA12 2237/4885CA1 3468/4885 |
| US-20040198986-A1 | 5-amino-1,3-substituted pyrazole-4-carboxylic acid amides of given formula, such as 5-Amino-1-tert-butyl-3-{4-[3-(2-fluoro-5-trifluoromethyl-phenyl)-ureido]-phenyl}-1H-pyrazole-4-carboxylic acid amide; treating cancer; receptor tyrosine kinase inhibitors | ERBB2, RET, ERBB4 | KMT2A 1055/4885CA12 4504/4885CA1 4069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.